John Libbey Eurotext

Innovations & Thérapeutiques en Oncologie

MENU

ProTcell: A platform for cellular therapy to rearm the immune system against cancer and infections based on the power of the thymus Volume 8, issue 6, November-December 2022

Figure 1.

Schéma illustrant le protocole clinique de l’essai NCT03879876, « Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients (HTLP Necker) ».

Figure 1. Schematic representation illustrating the clinical protocol of the NCT03879876 trial, “Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients (HTLP Necker)”.

Figure 2

Coupes histologiques de thymus de souris immunodéficientes NSG, 10 semaines après l’injection de progéniteurs lymphoïdes humains (ProTcell) (A), et de thymus de souris NSG ayant reçu des cellules CD34+ (B). En rouge : CD45+. En bleu : Keratin 14. En vert : Keratin 8.

Figure 2. Histological sections of the thymus of the NSG mouse, 10 weeks after injection of human lymphoid progenitors (ProTcell) (left), and the thymus of NSG mouse treated with CD34+ cells (right). Red: CD45+, blue: keratin 14, green: keratin 8.